IBDEI1MP ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28917,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28917,1,3,0)
 ;;=3^Other General Symptoms
 ;;^UTILITY(U,$J,358.3,28917,1,4,0)
 ;;=4^780.99
 ;;^UTILITY(U,$J,358.3,28917,2)
 ;;=^328568
 ;;^UTILITY(U,$J,358.3,28918,0)
 ;;=780.79^^167^1845^36
 ;;^UTILITY(U,$J,358.3,28918,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28918,1,3,0)
 ;;=3^General Weakness
 ;;^UTILITY(U,$J,358.3,28918,1,4,0)
 ;;=4^780.79
 ;;^UTILITY(U,$J,358.3,28918,2)
 ;;=^73344
 ;;^UTILITY(U,$J,358.3,28919,0)
 ;;=369.4^^167^1845^46
 ;;^UTILITY(U,$J,358.3,28919,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28919,1,3,0)
 ;;=3^Legal Blindness (USA Definition)
 ;;^UTILITY(U,$J,358.3,28919,1,4,0)
 ;;=4^369.4
 ;;^UTILITY(U,$J,358.3,28919,2)
 ;;=^268887
 ;;^UTILITY(U,$J,358.3,28920,0)
 ;;=413.9^^167^1845^5
 ;;^UTILITY(U,$J,358.3,28920,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28920,1,3,0)
 ;;=3^Angina Pectoris NEC/NOS
 ;;^UTILITY(U,$J,358.3,28920,1,4,0)
 ;;=4^413.9
 ;;^UTILITY(U,$J,358.3,28920,2)
 ;;=^87258
 ;;^UTILITY(U,$J,358.3,28921,0)
 ;;=300.00^^167^1845^6
 ;;^UTILITY(U,$J,358.3,28921,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28921,1,3,0)
 ;;=3^Anxiety
 ;;^UTILITY(U,$J,358.3,28921,1,4,0)
 ;;=4^300.00
 ;;^UTILITY(U,$J,358.3,28921,2)
 ;;=^9200
 ;;^UTILITY(U,$J,358.3,28922,0)
 ;;=716.90^^167^1845^8
 ;;^UTILITY(U,$J,358.3,28922,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28922,1,3,0)
 ;;=3^Arthropathy NOS
 ;;^UTILITY(U,$J,358.3,28922,1,4,0)
 ;;=4^716.90
 ;;^UTILITY(U,$J,358.3,28922,2)
 ;;=^66343
 ;;^UTILITY(U,$J,358.3,28923,0)
 ;;=314.00^^167^1845^9
 ;;^UTILITY(U,$J,358.3,28923,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28923,1,3,0)
 ;;=3^Attention Defic Nonhyperactive
 ;;^UTILITY(U,$J,358.3,28923,1,4,0)
 ;;=4^314.00
 ;;^UTILITY(U,$J,358.3,28923,2)
 ;;=^268351
 ;;^UTILITY(U,$J,358.3,28924,0)
 ;;=496.^^167^1845^17
 ;;^UTILITY(U,$J,358.3,28924,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28924,1,3,0)
 ;;=3^Chr Airway Obstruction NEC
 ;;^UTILITY(U,$J,358.3,28924,1,4,0)
 ;;=4^496.
 ;;^UTILITY(U,$J,358.3,28924,2)
 ;;=^24355
 ;;^UTILITY(U,$J,358.3,28925,0)
 ;;=585.3^^167^1845^21
 ;;^UTILITY(U,$J,358.3,28925,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28925,1,3,0)
 ;;=3^Chr Kidney Disease,Stage III
 ;;^UTILITY(U,$J,358.3,28925,1,4,0)
 ;;=4^585.3
 ;;^UTILITY(U,$J,358.3,28925,2)
 ;;=^332809
 ;;^UTILITY(U,$J,358.3,28926,0)
 ;;=585.4^^167^1845^22
 ;;^UTILITY(U,$J,358.3,28926,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28926,1,3,0)
 ;;=3^Chr Kidney Disease,Stage IV
 ;;^UTILITY(U,$J,358.3,28926,1,4,0)
 ;;=4^585.4
 ;;^UTILITY(U,$J,358.3,28926,2)
 ;;=^332810
 ;;^UTILITY(U,$J,358.3,28927,0)
 ;;=585.1^^167^1845^19
 ;;^UTILITY(U,$J,358.3,28927,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28927,1,3,0)
 ;;=3^Chr Kidney Disease,Stage I
 ;;^UTILITY(U,$J,358.3,28927,1,4,0)
 ;;=4^585.1
 ;;^UTILITY(U,$J,358.3,28927,2)
 ;;=^332807
 ;;^UTILITY(U,$J,358.3,28928,0)
 ;;=585.2^^167^1845^20
 ;;^UTILITY(U,$J,358.3,28928,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28928,1,3,0)
 ;;=3^Chr Kidney Disease,Stage II
 ;;^UTILITY(U,$J,358.3,28928,1,4,0)
 ;;=4^585.2
 ;;^UTILITY(U,$J,358.3,28928,2)
 ;;=^332808
 ;;^UTILITY(U,$J,358.3,28929,0)
 ;;=585.5^^167^1845^23
 ;;^UTILITY(U,$J,358.3,28929,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28929,1,3,0)
 ;;=3^Chr Kidney Disease,Stage V
 ;;^UTILITY(U,$J,358.3,28929,1,4,0)
 ;;=4^585.5
 ;;^UTILITY(U,$J,358.3,28929,2)
 ;;=^332811
 ;;^UTILITY(U,$J,358.3,28930,0)
 ;;=585.9^^167^1845^18
 ;;^UTILITY(U,$J,358.3,28930,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28930,1,3,0)
 ;;=3^Chr Kidney Disease NOS
 ;;^UTILITY(U,$J,358.3,28930,1,4,0)
 ;;=4^585.9
 ;;
 ;;$END ROU IBDEI1MP
